NightHawk Biosciences Confirms NYSE American Listing for Stock & Rights
Ticker: SCPX · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1476963
| Field | Detail |
|---|---|
| Company | Nighthawk Biosciences, Inc. (SCPX) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0002 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, exchange-listing, 8-K
TL;DR
**NHWK confirms NYSE American listing for common stock and purchase rights.**
AI Summary
NightHawk Biosciences, Inc. (NHWK) filed an 8-K on January 11, 2024, to update its registered securities. The filing confirms that its Common Stock, with a $0.0002 par value per share, is traded under the symbol NHWK on the NYSE American LLC. Additionally, the company's Common Stock Purchase Rights are also registered on the NYSE American LLC, though they do not have a specific trading symbol. This matters to investors as it clarifies the current listing status of their shares and any associated rights, ensuring transparency regarding where these securities can be traded.
Why It Matters
This filing provides clarity on where NightHawk Biosciences' common stock and purchase rights are officially listed and traded, which is crucial for investors to understand market access and liquidity.
Risk Assessment
Risk Level: low — This filing is purely informational, confirming existing listings, and does not introduce new financial risks or operational changes.
Analyst Insight
A smart investor would use this filing to confirm the current listing details for NHWK shares and rights, ensuring they are trading on the correct exchange and have accurate information for their portfolio management.
Key Numbers
- $0.0002 — par value per share (of NightHawk Biosciences' Common Stock)
Key Players & Entities
- NightHawk Biosciences, Inc. (company) — the registrant filing the 8-K
- NHWK (company) — trading symbol for Common Stock
- NYSE American LLC (company) — exchange where securities are registered
- $0.0002 (dollar_amount) — par value per share of Common Stock
- January 8, 2024 (date) — date of earliest event reported
- January 11, 2024 (date) — date the 8-K was filed
FAQ
What is the trading symbol for NightHawk Biosciences, Inc.'s Common Stock?
The trading symbol for NightHawk Biosciences, Inc.'s Common Stock is NHWK, as stated in the filing under 'Title of each class Trading Symbol(s)'.
On which exchange are NightHawk Biosciences, Inc.'s securities registered?
NightHawk Biosciences, Inc.'s Common Stock and Common Stock Purchase Rights are registered on the NYSE American LLC, according to the 'Name of each exchange on which registered' section.
What is the par value per share of NightHawk Biosciences, Inc.'s Common Stock?
The par value per share of NightHawk Biosciences, Inc.'s Common Stock is $0.0002, as specified in the filing under 'Common Stock, $0.0002 par value per share'.
Do NightHawk Biosciences, Inc.'s Common Stock Purchase Rights have a trading symbol?
No, the filing indicates that the Common Stock Purchase Rights have 'None' listed under 'Trading Symbol(s)'.
What was the earliest event reported date for this 8-K filing?
The earliest event reported date for this 8-K filing was January 8, 2024, as stated under 'Date of Report (date of earliest event reported)'.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-01-11 16:59:34
Key Financial Figures
- $0.0002 — nge on which registered Common Stock, $0.0002 par value per share NHWK NYSE America
Filing Documents
- nhwk_8k.htm (8-K) — 27KB
- 0001079973-24-000060.txt ( ) — 237KB
- nhwk-20240108.xsd (EX-101.SCH) — 3KB
- nhwk-20240108_def.xml (EX-101.DEF) — 26KB
- nhwk-20240108_lab.xml (EX-101.LAB) — 36KB
- nhwk-20240108_pre.xml (EX-101.PRE) — 25KB
- nhwk_8k_htm.xml (XML) — 5KB
01 Other Items
Item 8.01 Other Items On January 8, 2024, NightHawk Biosciences, Inc. ( the "Company") issued a press release announcing that it is changing the name of the Company to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. The Company will continue to operate its CDMO within the Scorpius BioManufacturing, Inc. subsidiary. In connection with the name change, the Company's ticker will change to SCPX. The Company has determined to effectuate the name change on January 22, 2024
01 Financial Statements and
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 8, 2024 (Incorporated by reference as Exhibit 99.1 to Form 8-K filed with the Securities and Exchange Commission on January 8, 2024) 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 11, 2024 NightHawk Biosciences, Inc. By: /s/ Jeff Wolf Name: Jeff Wolf Title: Chief Executive Officer